Safety Study of GBS Following Menactra Meningococcal Vaccination

CompletedOBSERVATIONAL
Enrollment

6,000,000

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2010

Conditions
Guillain-Barre Syndrome
Trial Locations (6)

19801

HealthCore, Inc., Wilmington

96817

Kaiser Permanente Center for Health Research Hawaii, Honolulu

02215

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston

02451

i3 Drug Safety, Waltham

Unknown

Aetna, Inc., Blue Bell

Highmark Blue Cross Blue Shield, Pittsburgh

All Listed Sponsors
collaborator

Aetna, Inc.

INDUSTRY

collaborator

HealthCore, Inc.

INDUSTRY

collaborator

Highmark Blue Cross Blue Shield

UNKNOWN

collaborator

i3 Drug Safety

OTHER

collaborator

Kaiser Permanente

OTHER

lead

Harvard Pilgrim Health Care

OTHER

NCT00575653 - Safety Study of GBS Following Menactra Meningococcal Vaccination | Biotech Hunter | Biotech Hunter